Contemporary dyslipidemia management: from risk assessment to precision lipid lowering
Romanian Medical Journal · 2026-09-30 · 73 (3) · 414
DOI: 10.37897/rmj.2026.3.15 ↗Abstract
Background and objectives. Dyslipidemia remains a major modifiable determinant of atherosclerotic cardiovascular disease (ASCVD), yet many patients fail to achieve recommended lipid targets. This narrative review examined contemporary approaches to lipid assessment, cardiovascular risk stratification, established lipid-lowering treatments, and emerging precision therapies. Methods. PubMed and Scopus were searched for studies published from 2017 through 2026 using terms related to dyslipidemia, lipid biomarkers, cardiovascular risk, lipid-lowering therapies, and emerging treatments. Publications were prioritized according to clinical relevance, methodological quality, and contribution to guideline recommendations or treatment efficacy and safety. Findings were qualitatively synthesized. No meta-analysis was performed. Results. LDL-C remained the principal therapeutic target, with ApoB, non-HDL cholesterol, and lipoprotein(a) providing complementary information in selected clinical settings. Statins, ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies have evidence supporting cardiovascular outcome benefits in defined populations. Inclisiran provides substantial LDL-C lowering, but cardiovascular outcome evidence remains pending. Obicetrapib has demonstrated lipid-lowering efficacy, whereas cardiovascular benefit has not been established. Lp(a)-targeted drugs and gene-editing approaches remain investigational. Notably, the phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular outcome endpoint in topline results reported in 2026. Conclusions. Contemporary dyslipidemia management combines risk-guided LDL-C lowering with complementary biomarkers and sustained reduction of lifetime exposure to atherogenic lipoproteins. Treatment decisions should distinguish therapies with demonstrated cardiovascular outcome benefits from agents whose evidence currently supports lipid lowering alone.
EUVIMED